Inhibition of pancreatic lipase by inhibitors such as orlistat is a principal therapeutic mechanism for suppressing the digestion of dietary triacylglycerols (lipolysis) and a strategy for treating obesity and hyperlipidemia [36]. The gene discussed is PNLIP; the disease is hyperlipidemia.